<DOC>
	<DOCNO>NCT01610102</DOCNO>
	<brief_summary>The primary objective study collect long term clinical follow-up data patient enrol PROGRESS AMS-1.0 study ass long term safety AMS-1.0</brief_summary>
	<brief_title>PROGRESS-AMS 1.0 Clinical Long Term Follow-Up</brief_title>
	<detailed_description>The first clinical experience AMS infrapopliteal artery demonstrate safety acceptable patency rate 12 month post implantation . These encouraging result lead initiation first trial treat human coronary lesion AMS name Clinical Performance angiographic Results Coronary Stenting Absorbable Metal Stents ( PROGRESS AMS-1 ) . Although ischemic driven target lesion revascularization rate 26.7 % ( 16/60 ) observe PROGRESS AMS-1 study , demonstrate biodegradable magnesium stent implant safely coronary artery , stent degrade intend without cause stent thrombosis , myocardial infarction death one year . No adverse device effect absorbable nature stent constituent detect . The continued clinical follow-up retrospective evaluation angiography IVUS film eligible patient enrol PROGRESS-AMS 1.0 give important information long term safety absorbable metal scaffold thus support improvement device .</detailed_description>
	<criteria>Signed informed consent form available prior clinical long term followup Patent sign inform consent form prior clinical long term followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>clinical follow-up</keyword>
	<keyword>7 year</keyword>
	<keyword>patient enrol main study</keyword>
</DOC>